Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells + autologous platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Yantai Yuhuangding Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
AMSCs + PRP is an experimental, autologous cell-based biologic therapy being investigated for the treatment of severe knee osteoarthritis. It consists of autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in autologous platelet-rich plasma (PRP). The therapy is administered via intra-articular injection directly into the knee joint. The mechanism of action involves the regenerative and immunomodulatory effects of the AMSCs, which are supported by the growth factors and bioactive proteins contained within the PRP carrier. This combination aims to repair damaged cartilage and reduce inflammation in the joint tissues. It is currently being evaluated in a Phase II clinical study (NCT04212728) by Yantai Yuhuangding Hospital.
- Other names
- amscs + prpautologous adipose-derived mesenchymal stromal cells + autologous platelet-rich plasma
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells + autologous platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells + autologous platelet-rich plasma.